LOW RISK ILLICIT DRUG LEVEL MONITORING

本提案中描述的研究详细说明了使用免疫测定结合表面增强拉曼散射（Sers）光谱检测和定量非法药物的程序。 由于Sers的使用，该技术具有高灵敏度的优点。 此外，Sers独特的表面敏感检测意味着可以在不洗掉指示剂抗原的情况下读取测定。 这使得可以容易地使该方法自动化，以微孔板形式快速筛选大量样品。 将使用已用Sers活性胶体修饰的微孔板来证明该测定。 Sers表面将用抗非法药物、染料标记的药物处理，并加工形成预处理的板。 这些将代表待开发的商业产品的一部分，并将进行耐久性测试。 通过将样品引入改良微孔板进行分析。 只有那些被捕获并取代表面上的报告缀合物的药物才会从微量滴定威尔斯孔中产生Sers光谱。 未被捕获的染料药物缀合物未被观察到，因为它们的光谱未被Sers效应增强。 我们将研究几种染料共轭物，在红色的吸收，以提高我们的技术的灵敏度。 我们将使用633 nm HeNe激光系统进行分析。 将用全血、唾液和汗液进行测试。目前的免疫测定方法困难、耗时，并且需要危险的放射性试剂。 我们取消的洗涤步骤使得目前的方法难以自动化，因为大多数样品需要强制洗涤以去除标记的药物。 本文提出的技术将提供一个定量的结果，无需洗涤，将非常容易自动化的大规模快速分析。 我们建议研究非法药物分析，但该方法可适用于所有免疫测定。

The research described in this proposal details a procedure for detecting and quantifying Illicit Drugs using an immunoassay coupled with surface enhanced Raman scattering (SERS) spectroscopy. The technique has the advantage of high sensitivity due to the use of SERS. In addition, the unique surface sensitive detection of SERS means that the assay can be read without washing away the indicator antigens. This makes it possible to easily automate this method for rapid screening of large numbers of samples in a microwell plate format. The assays will be demonstrated with microwell plates that have been modified with a SERS active colloid. The SERS surface will be treated with anti-illicit drug, dye-tagged drugs, and processed to form a pretreated plate. These will represent part of the commercial product to be developed and will be tested for durability. The analysis will be performed by sample introduction onto the modified microwell plate. Only those drugs that are captured and displace the reporter conjugates on the surface will produce SERS spectra from the microtiter wells. Dye drug conjugates that are not captured are not observed as their spectra are not enhanced by the SERS effect. We will investigate several dye conjugates that have absorptions in the red to enhance the sensitivity of our technique. We will use both a 633 nm HeNe laser system for the analysis. Tests will be made with whole blood, saliva, and perspiration. PROPOSED COMMERCIAL APPLICATION Current methods for immunoassay are difficult, time consuming, and require hazardous radioactive reagents. The washing step that we eliminate makes automation difficult in current methods since most samples requires strengent washing to remove the tagged drugs. The technique proposed here will provide a quantitative result without washing and will be very easily automated for large scale rapid analysis. We are proposing to look at illicit drug analysis, however, the methodology can be adapted to all immunoassays.